23andMe to Present at Upcoming Investor Conferences
October 12 2022 - 4:10PM
23andMe Holding Co. (Nasdaq: ME) (“23andMe”), a leading human
genetics and biopharmaceutical company with a mission to help
people access, understand, and benefit from the human genome,
announced today that management will be participating in investor
presentations at the following conferences:
- Credit Suisse Healthcare Conference on Wednesday, November 9,
2022
- Evercore ISI HEALTHCONx Conference on Tuesday, November 29,
2022
- Piper Sandler Healthcare Conference on Wednesday, November 30,
2022
Interested parties can access a live webcast of the
presentations on the investors section of the Company website at
investors.23andme.com under the “News & Events” menu. The
latest information on this and other events, including any changes
to presentation dates and times, can also be found there. A webcast
replay will be available at the same location for a limited time
within 24 hours after each event.
About 23andMe23andMe is a genetics-led consumer
healthcare and therapeutics company empowering a healthier future.
For more information, please visit investors.23andme.com.
Forward-Looking StatementsThis press release
contains forward-looking statements within the meaning of Section
27A of the Securities Act of 1933, as amended, and Section 21E of
the Securities Exchange Act of 1934, as amended, including
statements regarding the future performance of 23andMe’s businesses
in consumer genetics and therapeutics and the growth and potential
of its proprietary research platform. All statements, other than
statements of historical fact, included or incorporated in this
press release, including statements regarding 23andMe’s strategy,
financial position, funding for continued operations, cash
reserves, projected costs, plans, and objectives of management, are
forward-looking statements. The words "believes," "anticipates,"
"estimates," "plans," "expects," "intends," "may," "could,"
"should," "potential," "likely," "projects," "continue," "will,"
“schedule,” and "would" or, in each case, their negative or other
variations or comparable terminology, are intended to identify
forward-looking statements, although not all forward-looking
statements contain these identifying words. These forward-looking
statements are predictions based on 23andMe’s current expectations
and projections about future events and various assumptions.
23andMe cannot guarantee that it will actually achieve the plans,
intentions, or expectations disclosed in its forward-looking
statements and you should not place undue reliance on 23andMe’s
forward-looking statements. These forward-looking statements
involve a number of risks, uncertainties (many of which are beyond
the control of 23andMe), or other assumptions that may cause actual
results or performance to be materially different from those
expressed or implied by these forward-looking statements. The
forward-looking statements contained herein are also subject
generally to other risks and uncertainties that are described from
time to time in the Company’s filings with the Securities and
Exchange Commission, including under Item 1A, “Risk Factors” in the
Company’s most recent Annual Report on Form 10-K and in its
subsequent reports on Forms 10-Q and 8-K.Investors are cautioned
not to place undue reliance on any such forward-looking statements,
which speak only as of the date they are made. Except as required
by law, 23andMe does not undertake any obligation to update or
revise any forward-looking statements whether as a result of new
information, future events, or otherwise.
Investor Relations Contact: investors@23andMe.comMedia Contact:
press@23andMe.com
23andMe (NASDAQ:ME)
Historical Stock Chart
From Aug 2024 to Sep 2024
23andMe (NASDAQ:ME)
Historical Stock Chart
From Sep 2023 to Sep 2024